Acute Graft Versus Host Disease Clinical Trials

7 recruiting

About Acute Graft Versus Host Disease Clinical Trials

Looking for clinical trials for Acute Graft Versus Host Disease? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Acute Graft Versus Host Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Acute Graft Versus Host Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 3

Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT

Acute Graft Versus Host Disease
Anhui Provincial Hospital134 enrolled1 locationNCT07047456
Recruiting
Phase 1Phase 2

First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD)

Acute Graft Versus Host Disease
First Affiliated Hospital of Zhejiang University35 enrolled1 locationNCT07285889
Recruiting
Phase 4

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

Steroid-refractory Acute Graft Versus Host Disease
Novartis Pharmaceuticals36 enrolled17 locationsNCT06462469
Recruiting
Phase 1

Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies

Acute Graft Versus Host DiseaseHematopoietic and Lymphoid System Neoplasm
City of Hope Medical Center18 enrolled1 locationNCT05443425
Recruiting
Phase 3

Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD

Acute Graft Versus Host Disease
Peking University People's Hospital218 enrolled2 locationsNCT05921305
Recruiting
Phase 2

Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment

Acute Graft Versus Host Disease
Hospital Universitario Dr. Jose E. Gonzalez20 enrolled1 locationNCT06904599
Recruiting
Phase 2

An open label, study to evaluate the safety of Cannabidiol (CBD) for the prevention of Acute Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic cell transplantation.

Acute Graft Versus Host DiseaseHematopoietic Stem Cell Transplantation
Kalytera Therapeutics Israel Ltd36 enrolled2 locationsACTRN12619000623190
Recruiting
Phase 1

A study to evaluate the effect of food on the pharmakokinetics and cardiac function in male and female healthy volunteers who have been administered cannibidiol.

Acute Graft Versus Host Disease
Kalytera Australia Pty Ltd32 enrolled1 locationACTRN12619000443190
Recruiting
Phase 3

Use of Tocilizumab (TCZ) to prevent acute graft versus host disease (GVHD) randomized trial

Acute graft versus host disease (GVHD) post HLA-matched allogeneic haematopoietic progenitor cell transplantation (HPCT)
Royal Brisbane and Women's Hospital110 enrolled1 locationACTRN12614000266662
Recruiting
Phase 2

Use of Tocilizumab (TCZ) to prevent acute graft versus host disease (GVHD)

Acute graft versus host disease (GVHD) post HLA-matched allogeneic haematopoietic progenitor cell transplantation (HPCT)
Royal Brisbane and Women's Hospital18 enrolled1 locationACTRN12614000212651
Recruiting
Phase 2

Use of Tocilizumab (TCZ) to prevent acute graft versus host disease (GVHD)

Acute graft versus host disease (GVHD) post HLA-matched allogeneic haematopoietic progenitor cell transplantation (HPCT)
Royal Brisbane and Women's Hospital48 enrolled1 locationACTRN12612000726853
Recruiting
Phase 2

Phase II study of myeloablative allogeneic transplantation using pegylated G-CSF mobilised peripheral blood stem cells.

Acute Graft Versus Host Disease following allogeneic peripheral blood stem cell transplant from am HLA identical sibling for a haematological malignancy.
A/Prof Geoff Hill47 enrolled1 locationACTRN12605000460606